United States. Improving Regulatory Transparency for New Medical Therapies Act
URI(s)
Components
Work Begun
Form
- (lcgft) Statutes and codes
Variants
United States. Act to Amend the Controlled Substances Act with Respect to Drug Scheduling Recommendations by the Secretary of Health and Human Services, and with Respect to Registration of Manufacturers and Distributors Seeking to Conduct Clinical Testing
United States. Public Law 114-89
Identifies LC/NAF RWO
Exact Matching Concepts from Other Schemes
Sources
found: Improving Regulatory Transparency for New Medical Therapies Act, 2015, Public Law 114-89:129 Stat. 698 (An Act to Amend the Controlled Substances Act with Respect to Drug Scheduling Recommendations by the Secretary of Health and Human Services, and with Respect to Registration of Manufacturers and Distributors Seeking to Conduct Clinical Testing) citation title (Improving Regulatory Transparency for New Medical Therapies Act) 129 Stat. 703 (Approved November 25, 2015)
Instance Of
Scheme Membership(s)
Collection Membership(s)
Change Notes
2016-02-11: new
2016-02-12: revised
Alternate Formats
